Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.
作者信息
Yip Terry Cheuk-Fung, Wong Grace Lai-Hung, Wong Vincent Wai-Sun
机构信息
Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
出版信息
Clin Mol Hepatol. 2021 Apr;27(2):273-277. doi: 10.3350/cmh.2021.0019. Epub 2021 Feb 1.
Abstract
摘要
相似文献
1
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.免疫耐受期慢性乙型肝炎患者发生肝细胞癌的风险可忽略不计：神话还是事实？
Clin Mol Hepatol. 2021 Apr;27(2):273-277. doi: 10.3350/cmh.2021.0019. Epub 2021 Feb 1.
2
Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?未经治疗的慢性乙型肝炎患者发生肝细胞癌的风险：与HBeAg状态无关？
Clin Mol Hepatol. 2021 Jul;27(3):448-450. doi: 10.3350/cmh.2021.0130. Epub 2021 Jun 23.
3
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B.信件：慢性乙型肝炎免疫耐受期肝细胞癌的风险
Aliment Pharmacol Ther. 2020 Sep;52(5):911-912. doi: 10.1111/apt.15966.
4
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.在免疫耐受期的慢性乙型肝炎患者中，肝细胞癌发展的风险极低。
Aliment Pharmacol Ther. 2020 Jul;52(1):196-204. doi: 10.1111/apt.15741. Epub 2020 May 26.
5
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.信函：慢性乙型肝炎免疫耐受期肝细胞癌的风险——作者回复
Aliment Pharmacol Ther. 2020 Sep;52(5):913-914. doi: 10.1111/apt.15992.
6
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.免疫耐受期慢性乙型肝炎患者发生肝细胞癌和死亡的风险较高。
Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21.
7
Hepatitis B e Antigen--the dangerous endgame of hepatitis B.乙肝e抗原——乙肝的危险终局。
N Engl J Med. 2002 Jul 18;347(3):208-10. doi: 10.1056/NEJMe020060.
8
Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.信函：慢性乙型肝炎患者血清乙肝病毒DNA与肝细胞癌风险
Aliment Pharmacol Ther. 2021 Mar;53(6):761-762. doi: 10.1111/apt.16264.
9
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.慢性乙型肝炎严格定义的未经治疗免疫耐受期内 HCC 风险可忽略不计。
Eur J Intern Med. 2021 Feb;84:68-73. doi: 10.1016/j.ejim.2020.10.022. Epub 2020 Dec 4.
10
Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors' reply.信函：慢性乙型肝炎患者血清乙肝病毒DNA与肝细胞癌风险——作者回复
Aliment Pharmacol Ther. 2021 Mar;53(6):763. doi: 10.1111/apt.16278.
引用本文的文献
1
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States.美国慢性乙型肝炎灰色区和免疫耐受期患者肝细胞癌预计缓解情况
Dig Dis Sci. 2025 Apr;70(4):1547-1554. doi: 10.1007/s10620-025-08909-z. Epub 2025 Feb 20.
2
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma.治疗慢性乙型肝炎是弥漫性大 B 细胞淋巴瘤的良好预后因素。
Clin Mol Hepatol. 2023 Jul;29(3):794-809. doi: 10.3350/cmh.2023.0057. Epub 2023 May 17.
3
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.慢性乙型肝炎血清学免疫耐受期的长期预后和组织学评估的必要性。
Clin Mol Hepatol. 2023 Apr;29(2):482-495. doi: 10.3350/cmh.2022.0322. Epub 2023 Jan 5.
4
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.慢性乙型肝炎患者体力活动与肝细胞癌风险的关联
Cancers (Basel). 2021 Jul 8;13(14):3424. doi: 10.3390/cancers13143424.
本文引用的文献
1
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B.对于慢性乙型肝炎患者，生物标志物定义的免疫耐受期发生肝细胞癌的风险可忽略不计。
Clin Mol Hepatol. 2021 Apr;27(2):295-304. doi: 10.3350/cmh.2020.0216. Epub 2020 Dec 3.
2
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.慢性乙型肝炎严格定义的未经治疗免疫耐受期内 HCC 风险可忽略不计。
Eur J Intern Med. 2021 Feb;84:68-73. doi: 10.1016/j.ejim.2020.10.022. Epub 2020 Dec 4.
3
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.重复的 FIB-4 检测有助于识别发生严重肝脏疾病风险的个体。
J Hepatol. 2020 Nov;73(5):1023-1029. doi: 10.1016/j.jhep.2020.06.007. Epub 2020 Jul 1.
4
KASL clinical practice guidelines for management of chronic hepatitis B.《慢性乙型肝炎管理的KASL临床实践指南》
Clin Mol Hepatol. 2019 Jun;25(2):93-159. doi: 10.3350/cmh.2019.1002. Epub 2019 Jun 12.
5
Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.增强纤维化评分和肝硬度测量的改善反映了肝细胞癌风险的降低。
Aliment Pharmacol Ther. 2019 Jun;49(12):1509-1517. doi: 10.1111/apt.15269. Epub 2019 Apr 25.
6
Unmet need in chronic hepatitis B management.慢性乙型肝炎管理中的未满足需求。
Clin Mol Hepatol. 2019 Jun;25(2):172-180. doi: 10.3350/cmh.2018.0106. Epub 2019 Feb 12.
7
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.抗病毒治疗期间的正常 ALT 水平与慢性乙型肝炎患者发生肝脏事件的风险降低相关。
J Hepatol. 2018 Oct;69(4):793-802. doi: 10.1016/j.jhep.2018.05.009.
8
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展：美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
9
Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.慢性乙型肝炎病毒感染者免疫耐受期的管理：最新指南推荐。
Clin Mol Hepatol. 2018 Jun;24(2):108-113. doi: 10.3350/cmh.2017.0068. Epub 2018 Jan 22.
10
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.免疫耐受期慢性乙型肝炎患者发生肝细胞癌和死亡的风险较高。
Gut. 2018 May;67(5):945-952. doi: 10.1136/gutjnl-2017-314904. Epub 2017 Oct 21.
Zotero 插件